Related Experiment Video

Updated: Jul 27, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Clinical experience with COP-1 in multiple sclerosis

M B Bornstein1, A Miller, S Slagle

  • 1Department of Neurology/Neurosciences, Albert Einstein College of Medicine, New York, NY 10461.

Neurology
|July 1, 1988
PubMed

Insights

Cop-1, a polypeptide preparation, is explored for its potential in treating multiple sclerosis (MS). It stimulates myelin basic protein (MBP) to suppress experimental allergic encephalomyelitis (EAE), an animal model of MS.

Area of Science:

  • Neuroimmunology
  • Demyelinating Diseases
  • Pharmacology

Background:

  • Myelin basic protein (MBP) is a key component of the myelin sheath.
  • Experimental allergic encephalomyelitis (EAE) serves as an animal model for multiple sclerosis (MS).
  • MBP's role in EAE induction and suppression is context-dependent (adjuvant vs. saline).

Purpose of the Study:

  • To investigate Cop-1, a polypeptide preparation, for its therapeutic potential in multiple sclerosis (MS).
  • To evaluate the mechanism of Cop-1 in modulating the immune response related to myelin basic protein (MBP).

Main Methods:

  • Administration of Cop-1, a polypeptide preparation.
  • Assessment of its effects on myelin basic protein (MBP) and experimental allergic encephalomyelitis (EAE).

Main Results:

  • Cop-1 is designed to stimulate myelin basic protein (MBP).
  • MBP in Freund's complete adjuvant induces EAE, while MBP in saline suppresses EAE.
  • This differential effect of MBP provides a rationale for Cop-1's use in MS.

Conclusions:

  • Cop-1's mechanism involves stimulating MBP, potentially offering a therapeutic strategy for MS.
  • The study supports the rationale for using Cop-1 in managing multiple sclerosis based on MBP's immunomodulatory properties.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...